Radiometric and radiotranscriptomic reports in the prostate cancer research field—(such as MRI, PSMA‐PET/CT and ultrasound), combining either with transcriptomic or with prostate‐specific membrane antigen detection, have been developed to improve diagnosis, therapeutics and prognosis of prostate cancer—a comparison. The gene discussed is FOLH1; the disease is prostate cancer.